Boston Scientific Weaves a $1.16B Acquisition

Boston Scientific's road to transcarotid artery revascularization (TCAR) has been paved by Silk Road Medical – in the form of a $1.16 billion acquisition.

Silk Road Medical has long been considered one of the 25 Most Attractive Medtech M&A Targets for its innovative platform of products designed to prevent stroke in patients with carotid artery disease through the TCAR procedure.